Aerpio Initiates Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Diabetic Macular Edema
2/13/2014 9:12:37 AM
CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis®) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPß) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
Help employers find you! Check out all the jobs and post your resume.
comments powered by